Find the right fit for you - faster
Get tailored insights about working at Seres Therapeutics in one quick step.
Seres Therapeutics Snapshot
Our mission is to transform the lives of patients worldwide with revolutionary microbiome therapeutics.
Seres Therapeutics is a clinical stage biotechnology company developing new therapies comprised of rationally selected live bacteria consortia. We have a strong development pipeline and rigorous scientific underpinning. We are working to revolutionize treatment for a wide range of diseases by modulating the composition and function of the human microbiome.
We are an exceptional team of drug development and microbiome experts. Our leadership team, board of directors and scientific advisory board have vast experience in the discovery, development, regulatory approval, and successful commercialization of a wide range of therapeutic products.
Notably, our team pioneered the development and FDA approval of the first-ever oral live biotherapeutic, VOWST™, which was sold to Nestlé Health Science in September 2024.
We are an exceptional team of drug development and microbiome experts. Our leadership team, board of directors and scientific advisory board have vast experience in the discovery, development, regulatory approval, and successful commercialization of a wide range of therapeutic products.
Notably, our team pioneered the development and FDA approval of the first-ever oral live biotherapeutic, VOWST™, which was sold to Nestlé Health Science in September 2024.
